ARS Pharmaceuticals filings report beneficial ownership by a Millennium-affiliated group. Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander disclose shared voting and dispositive power over 5,194,497 and 5,916,030 common shares respectively, shown as 5.2% and 6.0% of the class on the cover pages.
The filing is a joint Schedule 13G/A amendment dated in late March 2026 and includes a Joint Filing Agreement among the four reporting parties. The statement clarifies that the securities are held by entities subject to voting control and investment discretion by Millennium-affiliated managers.
Positive
None.
Negative
None.
Insights
Joint 13G/A lists shared beneficial ownership positions by Millennium-affiliated entities.
The Schedule 13G/A amendment discloses that Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 5,194,497 shares (5.2%) and Millennium-affiliated filers report 5,916,030 shares (6.0%). These counts appear on the cover responses for Item 6/8/9/11.
The filing includes a Joint Filing Agreement dated March 30, 2026 and a clarification that holdings are held by entities under Millennium managers' voting or investment discretion. Subsequent filings would show changes in position if holders trade or reclassify holdings.
Key Figures
Shared dispositive power (Integrated Core):5,194,497 sharesShared dispositive power (Millennium):5,916,030 sharesForm type:Schedule 13G/A+2 more
5 metrics
Shared dispositive power (Integrated Core)5,194,497 sharescover page figure, 5.2% of class
Shared dispositive power (Millennium)5,916,030 sharescover page figure, 6.0% of class
Form typeSchedule 13G/AAmendment No. 1 (joint filing)
Joint Filing Agreement dateMarch 30, 2026Exhibit I signature date
Issuer principal office11682 El Camino Real, Suite 300ARS Pharmaceuticals principal executive office
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
shared dispositive powerregulatory
"Shared Dispositive Power 5,916,030.00"
Joint Filing Agreementregulatory
"Exhibit I: Joint Filing Agreement, dated as of March 30, 2026"
beneficially ownedregulatory
"Amount beneficially owned: See response to Item 9 on each cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What does the ARS (SPRY) Schedule 13G/A disclose?
It discloses shared beneficial ownership by Millennium-affiliated parties, including 5,194,497 and 5,916,030 shares. The amendment lists voting and dispositive power percentages of 5.2% and 6.0% and a Joint Filing Agreement dated March 30, 2026.
Who are the reporting parties on the 13G/A for SPRY?
The reporting parties are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. Addresses and citizenships are provided on the cover pages and signatures appear dated March 30, 2026.
How much voting or dispositive power is reported?
Integrated Core Strategies reports shared voting and dispositive power over 5,194,497 shares (5.2%); Millennium-related filers report 5,916,030 shares (6.0%). Item responses correspond to cover-page entries for Items 5–8 and 11.
Does the filing claim direct beneficial ownership by the individuals?
No. The filing states the securities are held by entities subject to voting control or investment discretion by Millennium managers and disclaims that this alone is an admission of beneficial ownership. The Joint Filing Agreement is attached as Exhibit I.
What is the date associated with this Schedule 13G/A amendment?
The cover shows a March date in late March 2026 and signatures are dated March 30, 2026. The Joint Filing Agreement is dated March 30, 2026 as well.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
ARS Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
82835W108
(CUSIP Number)
03/27/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
82835W108
1
Names of Reporting Persons
Integrated Core Strategies (US) LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,194,497.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,194,497.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,194,497.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.2 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
82835W108
1
Names of Reporting Persons
Millennium Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,916,030.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,916,030.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,916,030.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
82835W108
1
Names of Reporting Persons
Millennium Group Management LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,916,030.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,916,030.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,916,030.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
OO
SCHEDULE 13G
CUSIP Number(s):
82835W108
1
Names of Reporting Persons
Israel A. Englander
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,916,030.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,916,030.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,916,030.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
ARS Pharmaceuticals, Inc.
(b)
Address of issuer's principal executive offices:
11682 El Camino Real, Suite 300, San Diego, California 92130
Item 2.
(a)
Name of person filing:
Integrated Core Strategies (US) LLC
Millennium Management LLC
Millennium Group Management LLC
Israel A. Englander
(b)
Address or principal business office or, if none, residence:
Integrated Core Strategies (US) LLC
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Management LLC
399 Park Avenue
New York, New York 10022
Millennium Group Management LLC
399 Park Avenue
New York, New York 10022
Israel A. Englander
c/o Millennium Management LLC
399 Park Avenue
New York, New York 10022
(c)
Citizenship:
Integrated Core Strategies (US) LLC - Delaware
Millennium Management LLC - Delaware
Millennium Group Management LLC - Delaware
Israel A. Englander - United States
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See response to Item 9 on each cover page.
(b)
Percent of class:
See response to Item 11 on each cover page.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See response to Item 5 on each cover page.
(ii) Shared power to vote or to direct the vote:
See response to Item 6 on each cover page.
(iii) Sole power to dispose or to direct the disposition of:
See response to Item 7 on each cover page.
(iv) Shared power to dispose or to direct the disposition of:
See response to Item 8 on each cover page.
The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
See Exhibit I
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Integrated Core Strategies (US) LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/30/2026
Millennium Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/30/2026
Millennium Group Management LLC
Signature:
/s/ Gil Raviv
Name/Title:
Gil Raviv, Global General Counsel
Date:
03/30/2026
Israel A. Englander
Signature:
/s/ Israel A. Englander
Name/Title:
Israel A. Englander
Date:
03/30/2026
Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC
By: Integrated Holding Group LP, its Managing Member
By: Millennium Management LLC, its General Partner
Exhibit Information
Exhibit I: Joint Filing Agreement, dated as of March 30, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.
